The records of 47 patients with Ménière's syndrome were analyzed in a retrospective computerized study to determine the effect of different medical regimens on the long term course of hearing loss. Four treatment groups, including histamine (subcutaneous), other vasodilators (oral), vitamins, and untreated controls were examined. Results suggest that there was no statistically significant difference among the four groups in the rates or absolute level of hearing loss or SRT despite different therapeutic regimens. The ability of these agents to conserve hearing in patients with Ménière's syndrome remains unproven on the basis of clinical and laboratory evidence.
Download Full PDF Version (Non-Commercial Use)